Catherine F. Welsh

1.1k citations

24 papers · 858 indexed · h-index 14

Co-authors: Richard K. Assoian Martin A. Schwartz Kristin Roovers Jessie Villanueva Joel Moss Brian Diffey Dan Zhu Lilly Bourguignon
Topics: Cancer Treatment and Pharmacology (9 papers)Breast Cancer Treatment Studies (7 papers)HER2/EGFR in Cancer Research (6 papers)
Cited by: Cell Biology Immunology and Allergy Oncology
Journals: Journal of Biological Chemistry Journal of Clinical Oncology Nature Cell Biology
Partner nations: United States Singapore United Kingdom

In The Last Decade

Catherine F. Welsh

23 papers receiving 829 citations

Peers

Countries citing papers authored by Catherine F. Welsh

Since Specialization

Citations

This map shows the geographic impact of Catherine F. Welsh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine F. Welsh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine F. Welsh more than expected).

Fields of papers citing papers by Catherine F. Welsh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine F. Welsh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine F. Welsh. The network helps show where Catherine F. Welsh may publish in the future.

Co-authorship network of co-authors of Catherine F. Welsh

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine F. Welsh. A scholar is included among the top collaborators of Catherine F. Welsh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine F. Welsh. Catherine F. Welsh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeting regulated cell death pathways in cancers for effective treatment: a comprehensive review 2024 ·Frontiers in Cell and Developmental Biology ·Ruchi Saxena,Catherine F. Welsh,You‐Wen He	7
2	Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II–IIIc breast cancer 2011 ·Breast Cancer Research and Treatment ·Alberto J. Montero,C. Marcela Díaz‐Montero,Yehuda E. Deutsch,Judith Hurley,Leonidas G. Koniaris,Tihana Rumboldt,Saba Yasir,(unknown),(unknown),Eli Avisar,J. Slingerland,(unknown),Catherine F. Welsh,(unknown),Pearl H. Seo,Mark D. Pegram,Stefan Glück	90
3	Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer 2010 ·Breast Cancer Research and Treatment ·Christopher Lobo,Gilberto Lopes,(unknown),Aurelio Castrellon,(unknown),(unknown),(unknown),Judith Hurley,Isildinha M. Reis,Stephen P. Richman,Pearl H. Seo,Orlando Silva,Joyce M. Slingerland,(unknown),Catherine F. Welsh,Stefan Glück	68
4	Neoadjuvant platinum-based chemotherapy (CT) for triple-negative locally advanced breast cancer (LABC): Retrospective analysis of 125 patients 2009 ·Journal of Clinical Oncology ·José Pablo Leone,(unknown),(unknown),Mark D. Pegram,Catherine F. Welsh,(unknown),(unknown),(unknown),Carmen Gómez,Judith Hurley	19
5	Neoadjuvant dose-dense docetaxel, carboplatinum, and trastuzumab (ddTCH) chemotherapy for HER2 overexpressing breast cancer 2009 ·Journal of Clinical Oncology ·Soley Bayraktar,Ulas D. Bayraktar,Isildinha M. Reis,Mark D. Pegram,Catherine F. Welsh,(unknown),(unknown),(unknown),Judith Hurley	1
6	A Phase II Trial of Split, Low-Dose Docetaxel and Low-Dose Capecitabine: A Tolerable and Efficacious Regimen in the First-Line Treatment of Patients with HER2/neu–Negative Metastatic Breast Cancer 2008 ·Clinical Breast Cancer ·Orlando Silva,Gilberto Lopes,(unknown),Christopher Lobo,(unknown),Edgardo S. Santos,(unknown),(unknown),Isildinha M. Reis,Catherine F. Welsh,Joyce M. Slingerland,Judith Hurley,Stefan Glück	9
7	Phase II study of nab-paclitaxel, bevacizumab, and gemcitabine for first-line therapy of patients with HER2-negative metastatic breast cancer (MBC) 2008 ·Journal of Clinical Oncology ·Stefan Glück,(unknown),Isildinha M. Reis,(unknown),(unknown),(unknown),(unknown),Pearl H. Seo,(unknown),J. Slingerland,Catherine F. Welsh	5
8	Dose-dense docetaxel, carboplatinum and trastuzumab (ddTCH) as neoadjuvant therapy for human epidermal receptor 2 (HER2) positive breast cancer 2007 ·Journal of Clinical Oncology ·Hyo S. Han,(unknown),Marcelo Blaya,Stefan Glück,Joyce M. Slingerland,(unknown),Catherine F. Welsh,Judith Hurley	2
9	Methodology for Preservation of High Molecular-Weight RNA in Paraffin-Embedded Tissue 2005 ·Diagnostic Molecular Pathology ·Vladimir Vincek,Mehdi Nassiri,Norman L. Block,Catherine F. Welsh,Mehrdad Nadji,Azorides R. Morales	26
10	Weekly Docetaxel/Carboplatin as Primary Systemic Therapy for HER2-Negative Locally Advanced Breast Cancer 2005 ·Clinical Breast Cancer ·Judith Hurley,Isildinha M. Reis,Orlando Silva,Carmen Gómez,(unknown),(unknown),Catherine F. Welsh,Jaylen M. Powell,(unknown)	9
11	Deregulation of the Rho GTPase, Rac1, suppresses cyclin-dependent kinase inhibitor p21CIP1 levels in androgen-independent human prostate cancer cells 2004 ·Oncogene ·(unknown),Catherine F. Welsh,(unknown),Leah Lyons,(unknown),Eddy S. Yang,Kerry L. Burnstein	34
12	Rho GTPases as Key Transducers of Proliferative Signals in G1 Cell Cycle Regulation 2004 ·Breast Cancer Research and Treatment ·Catherine F. Welsh	49
13	Timing of cyclin D1 expression within G1 phase is controlled by Rho 2001 ·Nature Cell Biology ·Catherine F. Welsh,Kristin Roovers,Jessie Villanueva,(unknown),Martin A. Schwartz,Richard K. Assoian	262
14	A growing role for Rho family GTPases as intermediaries in growth factor- and adhesion-dependent cell cycle progression 2000 ·Biochimica et Biophysica Acta (BBA) - Reviews on Cancer ·Catherine F. Welsh,Richard K. Assoian	25
15	Interaction of CD44 variant isoforms with hyaluronic acid and the cytoskeleton in human prostate cancer cells 1995 ·Journal of Cellular Physiology ·Catherine F. Welsh,Dan Zhu,Lilly Bourguignon	43
16	Involvement of CD44 and its variant isoforms in membrane-cytoskeleton interaction, cell adhesion and tumor metastasis 1995 ·Journal of Neuro-Oncology ·Lilly Bourguignon,Naoko Iida,Catherine F. Welsh,Dan Zhu,Arnon Krongrad,(unknown)	46
17	[5] Activation of cholera toxin by ADP-ribosylation factors: 20-kDa guanine nucleotide-binding proteins 1994 ·Methods in enzymology on CD-ROM/Methods in enzymology ·Joel Moss,Randy S. Haun,Su-Chen Tsai,Catherine F. Welsh,Fang‐Jen S. Lee,S. Russ Price,Martha Vaughan	6
18	ADP-ribosylation factors: a family of ?20-kDa guanine nucleotide-binding proteins that activate cholera toxin 1994 ·Molecular and Cellular Biochemistry ·Catherine F. Welsh,Joel Moss,Martha Vaughan	44
19	Isolation of recombinant ADP-ribosylation factor 6, an approximately 20-kDa guanine nucleotide-binding protein, in an activated GTP-bound state. 1994 ·Journal of Biological Chemistry ·Catherine F. Welsh,Joel Moss,M Vaughan	13
20	Characterization of recombinant and endogenous ADP-ribosylation factors synthesized in Sf9 insect cells 1993 ·Biochemistry ·(unknown),Kimberly A. Muczynski,Catherine F. Welsh,S.J. Stanley,S C Tsai,Ronald Adamik,Patrick P. Chang,Joel Moss,Martha Vaughan	6

About Catherine F. Welsh

Catherine F. Welsh is a scholar working on Physiology, Oncology and Cancer Research, having authored 24 papers that have together received 858 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (9 papers), Breast Cancer Treatment Studies (7 papers) and HER2/EGFR in Cancer Research (6 papers). The work is most often cited by research in Cell Biology (261 citations), Immunology and Allergy (87 citations) and Oncology (306 citations). Catherine F. Welsh has collaborated with scholars based in United States, Singapore and United Kingdom. Frequent co-authors include Richard K. Assoian, Martin A. Schwartz, Kristin Roovers, Jessie Villanueva, Joel Moss, Brian Diffey, Dan Zhu, Lilly Bourguignon, Martha Vaughan and Judith Hurley. Their work appears in journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Nature Cell Biology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact